Leaders in Pharmaceutical Business Intelligence (LPBI) Group

3:15 – 3:45, 2014, Laurie Boyer “Long non-coding RNAs: molecular regulators of cell fate”

Reporter: Aviva Lev-ari, PhD, RN

LIVE from Kresge Auditorium @MIT

Key concepts captured:

• Heart development: network of genes responsible for cardiac disfunction
• Long non-coding RNAs (IncRNAs) as regulators of lineage commitment?
• potent and specific regulators of gene expression
• display cell type expression patterns
• LncRNAs: a new class of regulators of Heart development

1. Braveheart – necessary for formation of beating cardiomyocytes: ESCs, Mesoderm (MAS), Cardiac Precursors (CP), Cardiomyocytes, Polycomb repressive complex PRC2, PRC2 at key cardiac genes to alow for activation

• three Exons divided between cytoplasm and cytosome
• candidate IncRNAs orchestrate cardiac regeneration

2. RNA-Seq: characterization of LncRNAs: tissue differensiation, proliferation

• postnatal cardiomyocyt maturation involve – isolation of in vivo functional analysis of IncRNAs in postnatal CN maturation

1. Braveheart: – necessary for promoting cardiomycyte
2. LnncRNAs display stage-specific expression during postnatal CM maturation

• all genes chosen for screening as a function of time from birth and cell maturation and regeneration
• ventricular cells selected; FUNCTIONAL ANALYSIS OF CANDIDATE: control siRNA, Crim siRNA, LncRNA siRNA

Postnatal cardiomyocyte maturation

• Heart development,
• Regeneration and
• Cancer

3:15 – 3:45, 2014,  Laurie Boyer  “Long non-coding RNAs: molecular regulators of cell fate

@MIT – Summer Symposium 2014: RNA Biology, Cancer and Therapeutic Implications, June 13, 2014 8:30AM – 4:30PM, Kresge Auditorium @MIT

http://ki.mit.edu/news/symposium

REALTIME event coverage for the Scientific Media by Dr.  A. Lev-Ari 

in Open Access Scientific Journal of Leaders in Pharmaceutical Business Intelligence (LPBI)

http://pharmaceuticalintelligence.com

#pharmaIT,#BIOIT,#technews,#curation,#pharmanews,#mobilehealth,#mhealth,#science,#science2_0,#healtcare,#BIOIT14,#Boston ,@Biotech News,@MhealthForAll,@mHealthAlliance,@HCtrends,@mobilehealth360,@science 2_0
Laurie Boyer, PhD 
Irwin and Helen Sizer Career Development Associate Professor of Biology, Massachusetts Institute of Technology 
The Koch Institute for Integrative Cancer Research

Laurie A. Boyer, PhD, received a doctorate in biochemistry from the University of Massachusetts Medical School in 2001. Her work with Craig Peterson focused on dissecting the biochemical mechanisms of chromatin remodeling enzymes. She then joined the laboratories of Rudolf Jaenisch and Rick Young at Whitehead Institute for Biomedical Research as a postdoctoral fellow. Dr. Boyer is a pioneer in the development of high-throughput platforms for genome wide analysis of transcription factor binding sites as well as histone modifications and chromatin regulators in stem cells. During her postdoctoral studies, she discovered how Oct4, Sox2, and Nanog comprise a core transcriptional regulatory network that controls embryonic stem cell (ESC) pluripotency. She also illuminated a key role for Polycomb group proteins in regulating cell fate decisions during ESC differentiation. In 2006, Dr. Boyer was recognized as one of the world’s 50 top leaders in research, business or policy by Scientific American for her innovative work in understanding the genome of human ESCs. In 2007, she joined the faculty at the Massachusetts Institute of Technology as an assistant professor in the Biology Department. Dr. Boyer’s lab investigates how chromatin structure influences gene expression programs and ultimately cell fate and how failure to establish proper chromatin states can contribute to disease. In addition, her research team is interested in the role of noncoding RNA as well as non coding DNA elements in fine-tuning transcriptional programs during cell fate transitions.

Dr. Boyer is a Pew Scholar in the Biomedical Sciences and is the recipient of several early career awards including those from the Smith Family Foundation for Excellence in Biomedical Research as well as the Massachusetts Life Sciences Center.